Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX49 in Advanced/Metastatic Solid Tumors

12 listopada 2026 zaktualizowane przez: Shanghai Henlius Biotech

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HLX49 (Anti-HER2 Biparatopic and Bispecific ADC) in Participants With Advanced/Metastatic Solid Tumors

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of HLX49 in patients with advanced/metastatic solid tumors.

Przegląd badań

Status

Jeszcze nie rekrutacja

Warunki

Interwencja / Leczenie

Szczegółowy opis

In the phase Ia of this study, an accelerated titration and 3 + 3 dose escalation method will be adopted, and the patients will be administered with HLX49 at different doses via intravenous infusion. The DLT observation period lasts for 3 weeks after the first administration of HLX49.

In phase Ib of this study, the Safety Review Committee will recommend dose groups for expansion based on the safety, efficacy, and PK data of the dose escalation phase. The dose expansion part will enroll patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) who have previously failed first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars. Patients will be randomized to receive different doses of HLX49 or the active comparator (trastuzumab deruxtecan, T-DXd).

Typ studiów

Interwencyjne

Zapisy (Szacowany)

222

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  1. Willing and able to provide written informed consent and comply with the study protocol.
  2. Age: 18 to 75 years for Phase Ia; ≥ 18 years for Phase Ib. 3.Tumor Type & Prior Treatment: Phase Ia: Histologically or cytologically confirmed advanced or metastatic solid tumors that are refractory to standard treatment, or for which no standard treatment is available.

Phase Ib (GC/GEJC cohort): Histologically or cytologically confirmed advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) that has progressed during or after exactly one prior line of systemic therapy containing trastuzumab (or a biosimilar).

4.Confirmed HER2-positive status (Phase Ia: IHC 3+ or 2+; Phase Ib: IHC 3+ or IHC 2+/ISH+).

5.ECOG performance status score of 0 or 1. 6.At least one measurable lesion. 7.Life expectancy of more than 3 months. 8.Adequate washout period from prior treatments (e.g., at least 28 days for chemotherapy, radiotherapy, immunotherapy, or major surgery; at least 14 days for targeted therapy or hormone therapy) and recovery of previous treatment-related adverse events.

9.Must provide a tumor tissue sample for biomarker evaluation. 10.Adequate organ and bone marrow function as defined by protocol-specified laboratory tests.

11.Male and female participants with reproductive potential must agree to use highly effective contraception methods; female participants of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. History of other malignant tumors within 2 years prior to the first dose (with exceptions for cured early-stage cancers like cervical carcinoma in situ or non-melanoma skin cancer).
  2. History of severe eye diseases (e.g., severe keratopathy or moderate to severe dry eye).
  3. History of or current interstitial lung disease (ILD) or non-infectious pneumonitis requiring systemic steroids.
  4. Severe allergic reactions to monoclonal antibodies or allergy to any component of the investigational product.
  5. Active systemic infections requiring intravenous antibiotics.
  6. Requirement for treatment with systemic corticosteroids or other immunosuppressive medications within 2 weeks prior to the first dose.
  7. Clinically significant cardiovascular diseases, including but not limited to: severe/unstable angina, myocardial infarction within 6 months, symptomatic congestive heart failure, LVEF <50%, poorly controlled hypertension, or clinically significant prolonged QTc interval.
  8. Symptomatic or uncontrolled brain or meningeal metastases, or spinal cord compression.
  9. Active or suspected autoimmune diseases (exceptions apply for well-controlled type 1 diabetes and autoimmune hypothyroidism on replacement therapy).
  10. Unhealed major wounds or anticipation of major surgery during the study.
  11. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage.
  12. Use of strong CYP3A inhibitors or inducers within 2 weeks prior to the first dose.
  13. Active tuberculosis.
  14. Known history of immunodeficiency, including HIV, or history of solid organ transplantation.
  15. Active Hepatitis B (HBV) or Hepatitis C (HCV) infection (exceptions apply for stable/controlled HBV or HCV meeting specific viral load criteria).
  16. Pregnant or breastfeeding females.
  17. Subjects who are assessed as unsuitable for participating in this clinical study due to any clinical or laboratory abnormalities or other reasons by the investigator.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Ia (Dose Escalation)

Patients with advanced/metastatic solid tumors, who are refractory to standard treatment or for which no standard treatment is available.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Eksperymentalny: Ib HLX49 Dose 1 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Eksperymentalny: Ib HLX49 Dose 2 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Eksperymentalny: Ib HLX49 Dose 3 (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive the treatment once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Aktywny komparator: Ib Trastuzumab deruxtecan (Dose Expansion)

Patients with HER2-positive advanced/metastatic gastric or gastroesophageal junction adenocarcinoma (GC/GEJC), who have failed prior first-line systemic anti-tumor therapy containing trastuzumab or its biosimilars.

Patients with good tolerability and well controlled disease will receive Trastuzumab deruxtecan via intravenous infusion once every 3 weeks (Q3W), until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
The Dose-Limiting Toxicity (DLT) of HLX49 within 21 days after the first Administration
Ramy czasowe: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

DLT refers to the AEs that are determined to be related to the investigational product by the investigator, whose severity will affect the escalation of dose level. In this study, the DLT observation period lasts for 3 weeks (21 days) after the first administration of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
The maximum tolerated dose (MTD) of HLX49
Ramy czasowe: From first dose to the end of Cycle 1 (each cycle is 3 weeks).

The highest dose level, at which DLT is observed in no more than one of 6 evaluable patients, is defined as MTD of HLX49.

From first dose to the end of Cycle 1 (each cycle is 3 weeks).
RP2D
Ramy czasowe: Approximately up to 24 months.

The recommended phase 2 dose (RP2D) of HLX49 in participants with advanced/metastatic gastric/gastroesophageal junction adenocarcinoma.

Approximately up to 24 months.
Objective response rate (ORR) assessed by IRRC
Ramy czasowe: Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on independent radiographic review committee (IRRC) assessment.

Approximately up to 24 months.

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Objective response rate (ORR)
Ramy czasowe: Approximately up to 24 months.

Percentage of participants with complete response (CR) and partial response (PR) based on investigator assessment.

Approximately up to 24 months.
Duration of response (DOR)
Ramy czasowe: Approximately up to 24 months.

Length of time response continued based on investigator and IRRC assessment.

Approximately up to 24 months.
Progression-free survival (PFS)
Ramy czasowe: Approximately up to 24 months.

The PFS is defined as the time from the date of enrollment to the date of the first objective documentation of disease progression (as per RECIST v1.1) or death due to any cause, whichever occurred first.

Approximately up to 24 months.
Overall survival (OS)
Ramy czasowe: Approximately up to 24 months.

Time from the date of enrollment to the date of death for any cause.

Approximately up to 24 months.
Cmax
Ramy czasowe: Up to 21 days after the first dose.

Maximum serum concentration (Cmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
Tmax
Ramy czasowe: Up to 21 days after the first dose.

Time to maximum serum concentration (Tmax) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
T1/2
Ramy czasowe: Up to 21 days after the first dose.

Elimination half-life (t1/2) of HLX49, total antibody, and free payload.

Up to 21 days after the first dose.
ADA (anti-drug antibody)
Ramy czasowe: Approximately up to 24 months.

Positive rate of anti-HLX49 antibodies (ADA).

Approximately up to 24 months.
NAb (neutralizing antibody)
Ramy czasowe: Approximately up to 24 months.

Positive rate of neutralizing antibodies (NAb) against HLX49.

Approximately up to 24 months.

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Szacowany)

1 listopada 2026

Zakończenie podstawowe (Szacowany)

1 grudnia 2029

Ukończenie studiów (Szacowany)

1 grudnia 2030

Daty rejestracji na studia

Pierwszy przesłany

12 listopada 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

12 listopada 2026

Pierwszy wysłany (Rzeczywisty)

18 listopada 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

18 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

12 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • HLX49-FIH101

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .